**5PSQ-057 - EFFICACY AND SAFETY OF ADALIMUMAB IN THE TREATMENT OF INFLAMMATORY FACIAL GRANULOMA SECONDARY TO SILICONE**

M.L. Casanovas Moreno-Torres1, P. Yanes Sánchez1, L. Majuelos Aicart1, M.J. Revert Alarcón, V. Quesada Marques1, M.V. Morales León1.

1CHU Doctor Negrín, Hospitalary Pharmacist, Las Palmas de Gran Canaria, Spain.

### OBJETIVE

To describe the efficacy and safety of the use of adalimumab in patients diagnosed with inflammatory facial granuloma due to filler material (silicone).

### MATERIAL Y METHODS

**DESIGN**

A 3-month retrospective descriptive observational study of a patient under treatment with adalimumab for inflammatory facial granuloma due to silicone

**EFFICACY**

- Number of granulomas
- Size of granulomas

**SAFETY**

Adverse events (AE) occurrences associated with adalimumab

### RESULTS

62-year-old woman with inflammation compatible with silicone showed three lesions, one on the glabella and two on the cheeks

Adalimumab 40mg/2 weeks + doxycycline + hydroxychloroquine

From three initial lesions only lesion at the glabella level remains visible and palpable

The patient did not report any AE associated with the use of adalimumab

### CONCLUSION

- Adalimumab showed objective clinical benefits by achieving a significant reduction in the number and size of lesion.

- No adverse events were observed associated with this therapy.

- Together with the evidence collected, the use of TNF-α inhibitors can be considered as an adequate alternative to other treatments.

**L04- IMMUNOSUPPRESSANTS**